Heath Lukatch - 10 Jan 2023 Form 4 Insider Report for Vaxcyte, Inc. (PCVX)

Role
Director
Signature
Heath Lukatch, by /s/ Ron A. Metzger, Attorney-in-Fact
Issuer symbol
PCVX
Transactions as of
10 Jan 2023
Net transactions value
-$9,486
Form type
4
Filing time
12 Jan 2023, 15:33:18 UTC
Previous filing
14 Dec 2022
Next filing
08 Jun 2023
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction PCVX Common Stock Options Exercise $5,040 +315 +10% $16.00 3,440 10 Jan 2023 Direct
transaction PCVX Common Stock Sale $10,728 -233 -6.8% $46.04 3,207 10 Jan 2023 Direct F1, F2
transaction PCVX Common Stock Sale $3,799 -82 -2.6% $46.33 3,125 10 Jan 2023 Direct F1, F3

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction PCVX Stock Option (right to buy) Options Exercise $0 -315 -1.1% $0.000000 28,000 10 Jan 2023 Common Stock 315 $16.00 Direct F4
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan.
F2 The price reported is a weighted-average price. The shares were sold at prices ranging from $45.27 to $46.23. The reporting person will provide upon request to the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price.
F3 The price reported is a weighted-average price. The shares were sold at prices ranging from $46.29 to $46.385. The reporting person will provide upon request to the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price.
F4 1/3 of the shares subject to the option vest on June 11, 2021, and 1/36 of the shares vest monthly thereafter.